Abstract
Abstract The title compound, (+)-14,14-difluoro-4-demethoxydaunorubicin hydrochloride (9), was prepared starting from the readily available (−)-hydroxy ester (10). This synthesis featured the efficient synthetic route to (−)-14,14-difluoro-4-demethoxy-7-deoxydaunomycinone (20) employing the Reformatsky reaction of ethyl bromodifluoroacetate with the (−)-siloxy aldehyde (14) and previously developed glycosylation method in which trimethylsilyl trifluoromethanesulfonate was used as an activator. In P388 in vitro test, 9 was found to be fifty times more active than adriamycin (1). Prominent antitumor activity was also observed for 9 in P388 in vivo test.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have